KMDA
Price
$7.02
Change
+$0.01 (+0.14%)
Updated
Sep 12 closing price
Capitalization
409.23M
59 days until earnings call
LFCR
Price
$7.52
Change
-$0.25 (-3.22%)
Updated
Sep 12 closing price
Capitalization
281.31M
18 days until earnings call
Interact to see
Advertisement

KMDA vs LFCR

Header iconKMDA vs LFCR Comparison
Open Charts KMDA vs LFCRBanner chart's image
Kamada
Price$7.02
Change+$0.01 (+0.14%)
Volume$25.76K
Capitalization409.23M
Lifecore Biomedical
Price$7.52
Change-$0.25 (-3.22%)
Volume$135.1K
Capitalization281.31M
KMDA vs LFCR Comparison Chart in %
Loading...
KMDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LFCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KMDA vs. LFCR commentary
Sep 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KMDA is a Hold and LFCR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 14, 2025
Stock price -- (KMDA: $7.02 vs. LFCR: $7.52)
Brand notoriety: KMDA and LFCR are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: KMDA: 50% vs. LFCR: 102%
Market capitalization -- KMDA: $409.23M vs. LFCR: $281.31M
KMDA [@Pharmaceuticals: Generic] is valued at $409.23M. LFCR’s [@Pharmaceuticals: Generic] market capitalization is $281.31M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $65.68B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.94B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KMDA’s FA Score shows that 0 FA rating(s) are green whileLFCR’s FA Score has 1 green FA rating(s).

  • KMDA’s FA Score: 0 green, 5 red.
  • LFCR’s FA Score: 1 green, 4 red.
According to our system of comparison, LFCR is a better buy in the long-term than KMDA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KMDA’s TA Score shows that 5 TA indicator(s) are bullish while LFCR’s TA Score has 4 bullish TA indicator(s).

  • KMDA’s TA Score: 5 bullish, 4 bearish.
  • LFCR’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, KMDA is a better buy in the short-term than LFCR.

Price Growth

KMDA (@Pharmaceuticals: Generic) experienced а -1.68% price change this week, while LFCR (@Pharmaceuticals: Generic) price change was -0.13% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.26%. For the same industry, the average monthly price growth was +4.29%, and the average quarterly price growth was +53.41%.

Reported Earning Dates

KMDA is expected to report earnings on Nov 12, 2025.

LFCR is expected to report earnings on Oct 02, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.26% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KMDA($409M) has a higher market cap than LFCR($281M). LFCR has higher P/E ratio than KMDA: LFCR (51.23) vs KMDA (21.94). KMDA YTD gains are higher at: 18.574 vs. LFCR (1.211). KMDA has higher annual earnings (EBITDA): 34.2M vs. LFCR (-8.81M). KMDA has more cash in the bank: 66M vs. LFCR (8.27M). KMDA has less debt than LFCR: KMDA (11.4M) vs LFCR (131M). KMDA has higher revenues than LFCR: KMDA (170M) vs LFCR (129M).
KMDALFCRKMDA / LFCR
Capitalization409M281M146%
EBITDA34.2M-8.81M-388%
Gain YTD18.5741.2111,533%
P/E Ratio21.9451.2343%
Revenue170M129M132%
Total Cash66M8.27M799%
Total Debt11.4M131M9%
FUNDAMENTALS RATINGS
KMDA vs LFCR: Fundamental Ratings
KMDA
LFCR
OUTLOOK RATING
1..100
470
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
99
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
78100
PRICE GROWTH RATING
1..100
5048
P/E GROWTH RATING
1..100
396
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KMDA's Valuation (50) in the Biotechnology industry is somewhat better than the same rating for LFCR (99) in the Industrial Specialties industry. This means that KMDA’s stock grew somewhat faster than LFCR’s over the last 12 months.

KMDA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as LFCR (100) in the Industrial Specialties industry. This means that KMDA’s stock grew similarly to LFCR’s over the last 12 months.

KMDA's SMR Rating (78) in the Biotechnology industry is in the same range as LFCR (100) in the Industrial Specialties industry. This means that KMDA’s stock grew similarly to LFCR’s over the last 12 months.

LFCR's Price Growth Rating (48) in the Industrial Specialties industry is in the same range as KMDA (50) in the Biotechnology industry. This means that LFCR’s stock grew similarly to KMDA’s over the last 12 months.

LFCR's P/E Growth Rating (6) in the Industrial Specialties industry is somewhat better than the same rating for KMDA (39) in the Biotechnology industry. This means that LFCR’s stock grew somewhat faster than KMDA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KMDALFCR
RSI
ODDS (%)
Bullish Trend 6 days ago
65%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
62%
Bullish Trend 2 days ago
73%
Momentum
ODDS (%)
Bullish Trend 2 days ago
62%
Bearish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
64%
Bearish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
66%
Bearish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 6 days ago
65%
Bullish Trend 10 days ago
77%
Declines
ODDS (%)
Bearish Trend 3 days ago
66%
Bearish Trend 4 days ago
78%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
65%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
KMDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LFCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TISAX72.21-0.03
-0.04%
Nuveen S&P 500 Index I
FGTAX29.25-0.03
-0.10%
Fidelity Advisor Mega Cap Stock A
PEIRX26.27-0.03
-0.11%
Federated Hermes International Equity R6
NEJYX22.31-0.23
-1.02%
Natixis Vaughan Nelson Small Cap Y
GSVPX17.02-0.20
-1.16%
Goldman Sachs Small/Mid Cap Equity P

KMDA and

Correlation & Price change

A.I.dvisor tells us that KMDA and SIGA have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KMDA and SIGA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KMDA
1D Price
Change %
KMDA100%
+0.07%
SIGA - KMDA
29%
Poorly correlated
-1.65%
SGIOY - KMDA
27%
Poorly correlated
-1.10%
OGI - KMDA
26%
Poorly correlated
N/A
CRDL - KMDA
25%
Poorly correlated
N/A
LFCR - KMDA
23%
Poorly correlated
-3.22%
More